The life quality of patients with benign prostate hyperlasia treated medically in Hungary: a cross-sectional survey in six urological departments

DOI: 10.22591/magyurol.2017.4.kovacsa.173

Authors:
Kovács Ágnes dr.^1,2,3
1Budapesti Corvinus Egyetem, Gazdálkodástani Doktori Iskola, Budapest (igazgató: Michalkó Gábor dr.)
²Budapesti Corvinus Egyetem, Egészségügyi Közgazdaságtan Tanszék, Budapest (tanszékvezeto: Gulácsi lászló dr.)
³Boehringer-Ingelheim RCV, Magyarország (igazgató: Francesco Banchi dr.)

Summary

Objective: The aim of the study was to assess the quality of life of BPH patients receiving medication in urological care.
Patients and methods: A cross sectional survey was conducted in 2014 in 6 urological departments in Hungary. A total number of 246 medically treated males aged 18 years or over participated who had been diagnosed with benign prostatic hyperplasia. Patients’ mean age was 70,6 (SD 8,1) years and the average disease duration was 6,5 (SD 6,2) years.
Results: The average of International prostate Symptom Score was 12.8 (SD 6.3). Based on the total score 52 (23%), 136 (61%), and 35 (16%) patients belonged to the mild, moderate and severe benign prostatic hyperplasia subgroups. Health status of the patients measured with EQ-5D index and EQ VAS scores were 0.85 (SD 0.19) and 68.4 (SD 15.5), respectively and the difference between severity subgroups was significant for both.
Conclusion: Patients’ average EQ-5D index score was similar to the gender and age-matched population norm, except in age-groups 45–49 and 55–59 where patients’ scores were significantly lower and higher, respectively.

click here to read the full article